Skip to main content

Table 2 Comparison of clinical parameters between patients with initial CRP levels ≤3 mg/L versus > 3 mg/L

From: IL6 and CRPhaplotypes are associated with COPD risk and systemic inflammation: a case-control study

Characteristics CRP ≤ 3 mg/L
N = 146
CRP > 3 mg/L
N = 209
P-value
Years of age 62.1 (8.2) 65.7 (9.8) < 0.001
Male, N (%) 77 (53%) 142 (68%) 0.004
Current smoker, N (%) 40 (27%) 50 (24%) 0.460
Tobacco consumption, pack years-smoked 40.3 (19.0) 39.6 (18.2) 0.703
FEV1, liters 1.1 (0.5) 1.1 (0.5) 0.922
FEV1,%pred 41.6 (15.9) 41.9 (15.9) 0.846
FEV1/FVC, % 41.0 (11.8) 42.7 (11.8) 0.172
FVC, liters 3.0 (1.0) 3.0 (0.9) 0.884
FVC,%pred 87.5 (22.5) 85.4 (20.3) 0.373
BMI, kg/m2 24.0 (4.4) 25.7 (5.4) 0.001
PaO2, kPa 9.3 (1.5) 9.1 (1.3) 0.259
PaCO2, kPa 5.4 (0.8) 5.5 (0.8) 0.342
Long-term oxygen therapy, N (%) 30 (21%) 52 (25%) 0.205
6 minute walking distance, meters 445.9 (121.2) 401.1 (129.3) 0.001
Maximum workload, watts 77.2 (34.7) 69.2 (33.0) 0.037
Maximum workload,% pred 57.4 (23.6) 56.0 (26.4) 0.636
MRC dyspnea score 2 (2–4) 3 (2–4) 0.108
BODE index 4.1 (2.1) 4.4 (2.1) 0.264
Systolic blood pressure, mm/Hg 134.7 (21.7) 136.8 (24.4) 0.412
Diastolic blood pressure, mm/Hg 80.7 (12.5) 81.4 (13.5) 0.647
Charlson co morbidity index † 1 (1–7) 1 (1–8) 0.007
GOLD stages (%):    
Mild 2.1% 2.4% 0.891
Moderate 27.4% 23.9%  
Severe 35.6% 38.3%  
Very severe 34.9% 35.4%  
CRP, mg/L 1.1 (0.6–1.9) 9.4 (5.8–16.0) < 0.001
IL-6, pg/mL 1.3 (0.7–2.1) 3.5 (1.6–5.1) < 0.001
Fibrinogen, g/L 3.3 (3.0–3.6) 3.7 (3.4–4.0) < 0.001
  1. *Data presented as mean (standard deviation), median (inter quartile range) or No (%) unless stated otherwise
  2. † Median (range)